Practical guidance on the assessment of biosimilar monoclonal antibodies: A pharmacist's perspective

Realising the potential of biosimilars

Comment: Supporting a sustainable biosimilar solution

Comment: Use of biosimilar monoclonal antibodies in the clinic

Comment: Critical quality attributes of biosimilars

Symptomatic control in palliative medicine

Chemoimmunotherapy or BTK inhibition for patients with CLL

ASCO 2019 and vision for cancer control

The future potential of cannabis in healthcare

Driving the medicinal cannabis industry

Highlights from IGILUC 2019

Benefits of cannabis legalisation to patients and oncology professionals